HLUKY H Lundbeck A/S featured news, full reports, and detailed charts
H Lundbeck A/S (HLUKY/HLUKY.PK) Wrap Up:
H. Lundbeck A/S researches, develops, produces, markets, and sells pharmaceuticals for the treatment of the central nervous system (CNS) diseases in the United States, Europe, and internationally. Its products include Circadin for the treatment of primary insomnia; Cipralex, Lexapro, Sipralexa, Sipralex, Cipramil, Seropram, Cipram, and Celexa for the treatment of depression, generalized anxiety disorder, panic disorder, and social anxiety disorder; Ebixa and Ebix for the treatment of moderate to severe Alzheimer’s disease; Azilect for the treatment of Parkinson’s disease; Serdolect and Serlect for the treatment of schizophrenia; and Deanxit for the treatment of mild depression. The company a...H Lundbeck A/S (HLUKY:OTC)
|
Market Cap
3.8B
|
Total Revenue
12.6B
|
|
|
EBITDA
3.9B
|
DILUTED EPS TTM
8.89
|
|
|
P/E
11.1x
|
P/S
1.5x
|
|
|
Return On Asset
13.13
|
Return On Equity
21.76
|
|
| K = Thousands M = Millions B = Billions | ||
HLUKY Top Compensated Officers
Executives, Board Directors
Key developments for H Lundbeck A/S (HLUKY)
H. Lundbeck A/S reaffirmed its earnings outlook for the full year 2009. For the year, the company reiterated its guidance for revenue of between DKK 13.1 billion and DKK 13.6 billion and EBIT in the range DKK 2.8 billion-DKK 3 billion.
H. Lundbeck A/S reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported EBITDA of DKK 977 million, profit from operations of DKK 784 million, LBIT of DKK 30 million, profit before tax of DKK 754 million, profit of DKK 605 million or DKK 3.08 per diluted share on revenue of DKK 3,264 million compared to EBITDA of DKK 982 million, profit from operations of DKK 852 million, EBIT of DKK 33 million, profit before tax of DKK 884 million, profit of DKK 611 million or DKK 3.12 per diluted share on revenue of DKK 2,810 million for the same period a year ago. Cash flows used in operating activities was DKK 1,456 million compared to cash flows from operating activities of DKK 916 million for the same period a year ago. Property, plant and equipment investments were DKK 86 million compared to DKK 71 million for the same period in 2008. Return on equity was 17.3% compared to 8.6% for the same period a year ago. For the nine months, the company reported EBITDA of DKK 2,928 million, profit from operations of DKK 2,450 million, LBIT of DKK 119 million, profit before tax of DKK 2,331 million, profit of DKK 1,771 million or DKK 9.03 per diluted share on revenue of DKK 9,921 million compared to EBITDA of DKK 3,023 million, profit from operations of DKK 2,142 million, EBIT of DKK 49 million, profit before tax of DKK 2,157 million, profit of DKK 1,538 million or DKK 7.81 per diluted share on revenue of DKK 8,629 million for the same period a year ago. Cash flows used in operating activities was DKK 2,406 million compared to cash flows from operating activities of DKK 2,151 million for the same period a year ago. Property, plant and equipment investments were DKK 171 million compared to DKK 112 million for the same period in 2008. Return on equity was 22.1% compared to 21.2% for the same period a year ago.
H. Lundbeck A/S expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
HLUKY Competitors
| Company | Last | Change |
| Caraco Pharmaceutical Labs, Ltd. | $4.10 USD | +0.08 |
| Cephalon Inc | $59.61 USD | -0.10 |
| Elan Corporation | €4.36 EUR | +0.039 |
| Forest Laboratories Inc | $29.57 USD | +0.46 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | HLUKY | Industry Range |
| Price/Earnings | 11.1x |
|
| Price/Sales | 1.5x |
|
| Price/Book | 2.3x |
|
| Price/Cash Flow | 11.1x |
|
| TEV/Sales | 1.0x |
|
|
HLUKY |
||
HLUKY transactions
| Type Date |
Target |
|
Merger/Acquisition
October 6, 2009 |
Elaiapharm S.A. |
|
Merger/Acquisition
July 7, 2009 |
NeuronIcon ApS |
|
Merger/Acquisition
July 7, 2009 |
LifeHealth Limited |